Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.13, 2026.4.14
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: In 2026, the Qiming Weekly gets a fresh upgrade. Published every week, it features ten handpicked major updates from Qiming Venture Partners' portfolio companies, covering funding milestones and breakthrough developments.
Every step entrepreneurs take in the wave of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to follow along as we track the milestone moments of our portfolio companies.
Funding News
Shengshu Technology Closes Nearly RMB 2 Billion Series B Round
Recently, Qiming Venture Partners portfolio company Shengshu Technology announced the completion of a nearly RMB 2 billion Series B financing round. The proceeds will fund R&D for general world model technology, industrial deployment, and global talent acquisition. This round will help Shengshu Technology solidify the foundational capabilities of its general world model, accelerate technology commercialization and ecosystem building, maintain its leadership in the general world model track, and drive the deep integration of artificial general intelligence with physical industries.
Shengshu Technology builds on a foundation world model as its core infrastructure, offering Vidu — a world generation model for digital content — and Motus — a world action model for physical embodied intelligence — to create a complete technical closed loop of "understanding-generation-action," with the goal of building a general intelligence system that connects digital and physical worlds.
Its Vidu series models feature cinema-grade audio and video generation capabilities, pioneering "reference-to-video" technology. The Vidu Q3 model topped international authoritative AI benchmark leaderboards. The company serves multiple industries through MaaS, SaaS, and Alibaba Cloud Bailian. Its open-source unified world action model Motus, built on the UniDiffuser architecture, achieves unified multimodal representation, validates embodied foundation model scaling laws, and improves multi-task success rates by approximately 40% over international mainstream models — advancing robots toward unified intelligent agents.
Major Partnerships
01/ Biren Technology First to Complete Adaptation of Zhipu AI's New Flagship Model
Recently, Qiming Venture Partners portfolio company Zhipu AI (02513.HK) officially launched and open-sourced its next-generation flagship model GLM-5.1. As the world's strongest open-source model to date, GLM-5.1 achieves significant breakthroughs in long-horizon task processing capabilities. Qiming portfolio company Biren Technology (06082.HK) completed same-day adaptation of its Bili™ 166 series products, becoming one of the first domestic GPU manufacturers to support GLM-5.1.
Biren Technology conducted full-stack deep optimization targeting GLM-5.1's core features: 744B MoE architecture, 200K long context, and DSA sparse attention. The Bili™ 166 series comprises data-center-grade training and inference chips capable of meeting trillion-parameter model demands, widely deployed in large language models, multimodal AIGC, and image and speech processing. With exceptional technical maturity and out-of-the-box usability, the Bili™ 166 series significantly lowers the barrier for developers to deploy and apply models, enabling domestic SOTA (state-of-the-art) large models to scale through full-stack capabilities and driving the practical, accessible adoption of AI applications.
02/ WeRide Partners with Zhonghuanjie on Strategic Cooperation
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology firm WeRide (NASDAQ:WRD, 0800.HK) officially released its next-generation L4 Robosweeper — the autonomous road sweeper S3 and autonomous multi-function washing sweeper S5 — and announced a strategic partnership with Zhonghuanjie Group Co., Ltd. to jointly advance the large-scale deployment of smart sanitation across diverse urban scenarios. Per the agreement, Zhonghuanjie will purchase at least 300 autonomous road sweeper S3 units from WeRide over five years, with the first 100 to be delivered within one year, fully demonstrating the commercial strength of WeRide's Robosweeper product line in securing large orders immediately upon launch.
Currently, WeRide Robosweeper operates in over 40 cities nationwide and has entered international markets including Singapore, Slovakia, and Romania. This simultaneous product launch and strategic partnership will further accelerate WeRide's global large-scale deployment of smart sanitation.
03/ Gan & Lee Pharmaceuticals Signs Exclusive Licensing Deal with Korean Pharma Leader JW
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced an exclusive licensing agreement with leading Korean pharmaceutical company JW Pharmaceutical. The two parties will collaborate on the clinical development, regulatory filing, and commercialization in Korea of Gan & Lee's self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) biweekly formulation — Bofanglutide injection (development code: GZR18).
This marks Gan & Lee's third overseas licensing deal for Bofanglutide injection, following partnerships in Latin America and India. According to Grand View Research, the Asia-Pacific GLP-1RA market reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, representing a 14% CAGR — one of the fastest-growing regions globally. Current GLP-1 drug penetration remains extremely low, indicating massive growth potential. As a mature market in Asia-Pacific, Korea's GLP-1RA market reached USD 526 million in 2025 and is expected to grow to USD 1.6 billion by 2033. With high acceptance of innovative drugs and strong patient payment capacity, Korea has become a strategic gateway for multinational pharmaceutical companies entering East Asia. Gan & Lee's global map for its GLP-1RA biweekly formulation Bofanglutide is taking shape at an accelerating pace.
04/ UBTECH Signs Strategic Agreement with Dematic Technology
Recently, Qiming Venture Partners portfolio company UBTECH (09880.HK) and Dematic Technology Group Co., Ltd. held a strategic cooperation signing ceremony in Shanghai, formally inking their partnership. UBTECH and Dematic will jointly advance the large-scale deployment and commercial application of humanoid robot technology in core scenarios including intelligent manufacturing and smart logistics, marking a new phase in UBTECH's deep synergy between embodied intelligence and industrial smart logistics.
With "technology synergy, scenario deepening, and ecosystem co-building" as their strategic axis, the two parties will fully expand cooperation across five core directions: joint technology R&D, deep scenario adaptation, collaborative breakthroughs in core components, joint venture operations, and embodied data collection coordination. Taking this strategic partnership as a new starting point, UBTECH and Dematic will drive innovation as the core engine, prioritize value delivery, and pursue global expansion as the long-term goal — continuously increasing R&D investment and scenario expansion to jointly build an open, collaborative, and mutually beneficial global ecosystem for embodied intelligence and industrial logistics, leading industrial smart logistics into a new era of human-machine integration.
05/ Zai Lab Enters Global Clinical Research Collaboration with Amgen
Qiming Venture Partners portfolio company Zai Lab (NASDAQ:ZLAB, 09688.HK) recently announced a global clinical research collaboration with Amgen to evaluate zocilurtatug pelitecan (zoci, formerly ZL-1310), Zai Lab's clinical-stage delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), in combination with Amgen's IMDELLTRA® (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE®) therapy, for patients with extensive-stage small cell lung cancer (ES-SCLC).
As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study evaluating the safety and efficacy of zoci combined with IMDELLTRA® in ES-SCLC patients. Zai Lab retains full ownership of zoci and will supply clinical trial materials to Amgen. Dr. Rafael G. Amado, President and Global Head of R&D at Zai Lab, stated: "This dual-targeting combination strategy has the potential to improve response rates and depth of response for systemic and intracranial treatment, address resistance mechanisms, and open new treatment paradigms for small cell lung cancer patients. These two therapies leverage complementary mechanisms of action — our ADC delivers a potent cytotoxic payload directly to DLL3-expressing tumor cells, while the T-cell engager is designed to activate T cells by binding the same antigen to trigger anti-tumor immune responses."
Product Launches
01/ Unisound's U2Claw Desktop AI Agent Goes Live
Recently, Qiming Venture Partners portfolio company Unisound (09678.HK) officially launched its new desktop AI Agent product U2Claw. Positioned as a "get-things-done" desktop AI Agent, it directly executes desktop tasks on behalf of users rather than merely offering Q&A suggestions.
Key product highlights: (1) Cross-platform execution: Natively integrates with WeChat, DingTalk, Lark, QQ, and other mainstream platforms, enabling "send commands from mobile, auto-execute on desktop" — with automatic parsing and archiving of forwarded files, and one-click meeting minutes generation from group chats. (2) Dual security and cost optimization: Multi-layer protection through real-time system monitoring, end-to-end encryption, firewall blocking, and skill security scanning, with sensitive data processed locally in a closed loop; triple-technology cost control through context-aware compression, redundant instruction filtering, and task priority scheduling. (3) Comprehensive professional skills: Deep integration of speech recognition, speech synthesis, and document processing core modules, combined with vertical domain capabilities in healthcare and other sectors — ready to use out of the box without complex prompt engineering. (4) Deep Agent ecosystem synergy: Deep coordination with mainstream Agent frameworks including OpenClaw/AutoClaw, fully supporting the "perceive environment → plan actions → execute tasks" closed loop, with an official standardized skill library for efficient adaptation to various automation and GUI interaction scenarios.
02/
Infinigence AI Launches InfiniClaw Box for On-Device Cloud-Integrated Secure Desensitization
Recently, Qiming Venture Partners portfolio company Infinigence AI officially launched InfiniClaw Box, addressing OpenClaw cloud privacy risks, limited on-device computing power, and lack of full-modality secure desensitization capabilities with an on-device cloud-integrated secure desensitization solution. InfiniClaw Box innovates a three-stage "local desensitization — cloud processing — local restoration" on-device cloud-integrated secure desensitization inference scheme, ensuring private data never goes to the cloud, data never leaves the box, and capabilities remain fully intact.
Currently, Infinigence AI's InfiniClaw Box has established deep cooperation with multiple chip companies, smart terminal device makers, and application companies — including Axera and Cix Technology — across underlying chip adaptation, external terminal device interconnection, and upper-layer application scenario exploration.
03/
DeepWise Unveils AI4S Education and Research Product Matrix
Recently, Qiming Venture Partners portfolio company DeepWise successfully held its "2026 Partner Conference" in Beijing. Centered on the theme "Deepening AI for Science, Gathering Momentum for Win-Win Cooperation," the conference brought together experts and partners from education, research, and industry to exchange insights on the latest advances, practical implementations, and ecosystem collaboration in AI for Science (AI4S). At the conference, DeepWise presented three core solutions — "Bohr Science Navigator," "Singularity Classroom University Edition," and "Smart Classroom for Secondary Schools" — and reached agreements with multiple partners, further driving AI for Science from research scenarios toward the full education chain and industrial applications, accelerating the construction of a new ecosystem for collaborative industry-academia-research development.
"Bohr Science Navigator" focuses on upgrading research information infrastructure, providing a new-generation AI academic platform for universities, research institutes, and corporate R&D departments to support efficient organization and application of research information, with flexible deployment and rapid access. "Singularity Classroom University Edition" targets AI curriculum system building in higher education, creating a teaching platform covering courses, practice, and experiments around the concept of "integrated learning, research, practice, and competition," with customizable solutions for multiple disciplines. "Smart Classroom for Secondary Schools" focuses on AI literacy education for middle schools, combining theory and practice to build a cultivation system adapted to secondary students' growth paths, with competition-grade platforms enabling a "learning-competition integration" closed loop.
R&D Progress
Insilico Medicine Nominates Potential Best-in-Class NR3C1 Selective Antagonist ISM6200
Recently, Qiming Venture Partners portfolio company Insilico Medicine (03696.HK) announced the nomination of ISM6200, a potent, potentially best-in-class NR3C1 inhibitor, as a preclinical candidate compound (PCC) for the treatment of ovarian cancer, Cushing's syndrome, and other diseases associated with excess cortisol including obesity related to high glucocorticoid levels. The discovery and optimization of this candidate was driven by Chemistry42, the generative chemistry engine under Insilico Medicine's Pharma.AI platform, and its core modules.
Preclinical data shows ISM6200 is a small-molecule NR3C1 antagonist with low drug-drug interaction (DDI) risk and demonstrates superior in vivo efficacy across multiple animal models. ISM6200 also exhibits favorable physicochemical properties, stability, and developability, laying a solid foundation for subsequent clinical development. Since 2021, Insilico Medicine has nominated 29 PCCs, obtained clinical trial approvals for 12 candidate drugs, advanced 3 drugs to Phase II clinical trials with one Phase IIa trial completed; the company has also entered into over 10 business development partnerships in 2025 alone, fully demonstrating the high quality and rigorous standards of its self-developed programs.
Past Issues
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.12, 2026.4.7
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching USD 9.5 billion. Since inception, the firm has focused on investing in early and growth-stage outstanding companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu AI (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.